^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    polyinosinic:polycytidylic acid (BO-112)

    i
    Other names: BO-112, BO 112, BO112, Poly I:C, nanoplexed Poly IC, nanoplexed Poly I:C
    Associations

    News

    Trials
    Company:
    Highlight Therap
    Drug class:
    TLR3 agonist, EIF2AK2 activator, IFIH1 activator, PMAIP1 stimulant, RIG-I stimulant
    Related drugs:
    Associations

    News

    Trials
    8d
    KEYNOTE-B77: BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (clinicaltrials.gov)
    P2, N=42, Completed, Highlight Therapeutics | Active, not recruiting --> Completed
    Trial completion
    |
    BRAF (B-raf proto-oncogene) • CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • polyinosinic:polycytidylic acid (BO-112)
    9ms
    NCI-2019-08556: Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • polyinosinic:polycytidylic acid (BO-112)
    1year
    KEYNOTE-A06: Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis (clinicaltrials.gov)
    P2, N=18, Terminated, Highlight Therapeutics | Phase classification: P2a --> P2
    Phase classification • Combination therapy
    |
    RAS wild-type • EGFR positive
    |
    Keytruda (pembrolizumab) • polyinosinic:polycytidylic acid (BO-112)
    over1year
    SPOTLIGHT204: Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC) (clinicaltrials.gov)
    P2, N=60, Recruiting, Highlight Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    |
    polyinosinic:polycytidylic acid (BO-112)
    over1year
    SPOTLIGHT204: Clinical Trial to Evaluate Safety, Tolerability and Preliminary Efficacy of BO-112 in Patients With BCC (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Highlight Therapeutics
    New P2 trial
    |
    polyinosinic:polycytidylic acid (BO-112)
    over1year
    Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C. (PubMed, J Immunother Cancer)
    Intratumoral injection of poly(I:C) sensitizes MHClow tumors to the antitumor effects of artLCMV-E7E6, resulting in a potent therapeutic synergy.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CCL3 (C-C Motif Chemokine Ligand 3) • IFNA1 (Interferon Alpha 1) • BATF3 (Basic Leucine Zipper ATF-Like Transcription Factor 3)
    |
    polyinosinic:polycytidylic acid (BO-112)
    almost2years
    NCI-2019-08556: Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2024 --> Jan 2025
    Trial completion date • Trial primary completion date • Surgery
    |
    Opdivo (nivolumab) • polyinosinic:polycytidylic acid (BO-112)
    almost2years
    KEYNOTE-B77: BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, Highlight Therapeutics | Trial completion date: Dec 2023 --> Aug 2024
    Trial completion date • Combination therapy
    |
    BRAF (B-raf proto-oncogene) • CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • polyinosinic:polycytidylic acid (BO-112)
    almost2years
    Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors (clinicaltrials.gov)
    P1, N=44, Completed, Highlight Therapeutics | Terminated --> Completed
    Trial completion • Combination therapy
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • polyinosinic:polycytidylic acid (BO-112)
    almost3years
    Intratumoral BO-112 in combination with radiotherapy synergizes to achieve CD8 T-cell-mediated local tumor control. (PubMed, J Immunother Cancer)
    This study demonstrates that local BO-112 immunotherapy and focal irradiation may act in synergy to achieve local tumor control. Irradiation plus BO-112 in one of the tumor lesions enhanced the therapeutic effects on distant irradiated lesions that were not injected with BO-112, suggesting strategies to treat oligometastatic patients with lesions susceptible to radiotherapy and with at least one tumor accessible for repeated BO-112 intratumoral injections.
    Journal • Combination therapy
    |
    CALR (Calreticulin) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1)
    |
    polyinosinic:polycytidylic acid (BO-112)
    3years
    NCI-2019-08556: Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Jonsson Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=20 --> 14
    Enrollment closed • Enrollment change • Surgery
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • polyinosinic:polycytidylic acid (BO-112)
    over3years
    Noelia: Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Clinica Universidad de Navarra, Universidad de Navarra | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • polyinosinic:polycytidylic acid (BO-112)